CY1119161T1 - Μιγμα rp/sp gemcitabine-[phenyl-(benzyloxy-l-alaninyl)]-phosphate - Google Patents
Μιγμα rp/sp gemcitabine-[phenyl-(benzyloxy-l-alaninyl)]-phosphateInfo
- Publication number
- CY1119161T1 CY1119161T1 CY20171100539T CY171100539T CY1119161T1 CY 1119161 T1 CY1119161 T1 CY 1119161T1 CY 20171100539 T CY20171100539 T CY 20171100539T CY 171100539 T CY171100539 T CY 171100539T CY 1119161 T1 CY1119161 T1 CY 1119161T1
- Authority
- CY
- Cyprus
- Prior art keywords
- alaninyl
- gemcitabine
- benzyloxy
- phenyl
- phosphate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J27/00—Catalysts comprising the elements or compounds of halogens, sulfur, selenium, tellurium, phosphorus or nitrogen; Catalysts comprising carbon compounds
- B01J27/06—Halogens; Compounds thereof
- B01J27/128—Halogens; Compounds thereof with iron group metals or platinum group metals
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y20/00—Nanooptics, e.g. quantum optics or photonic crystals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01S—DEVICES USING THE PROCESS OF LIGHT AMPLIFICATION BY STIMULATED EMISSION OF RADIATION [LASER] TO AMPLIFY OR GENERATE LIGHT; DEVICES USING STIMULATED EMISSION OF ELECTROMAGNETIC RADIATION IN WAVE RANGES OTHER THAN OPTICAL
- H01S5/00—Semiconductor lasers
- H01S5/30—Structure or shape of the active region; Materials used for the active region
- H01S5/34—Structure or shape of the active region; Materials used for the active region comprising quantum well or superlattice structures, e.g. single quantum well [SQW] lasers, multiple quantum well [MQW] lasers or graded index separate confinement heterostructure [GRINSCH] lasers
- H01S5/343—Structure or shape of the active region; Materials used for the active region comprising quantum well or superlattice structures, e.g. single quantum well [SQW] lasers, multiple quantum well [MQW] lasers or graded index separate confinement heterostructure [GRINSCH] lasers in AIIIBV compounds, e.g. AlGaAs-laser, InP-based laser
- H01S5/34326—Structure or shape of the active region; Materials used for the active region comprising quantum well or superlattice structures, e.g. single quantum well [SQW] lasers, multiple quantum well [MQW] lasers or graded index separate confinement heterostructure [GRINSCH] lasers in AIIIBV compounds, e.g. AlGaAs-laser, InP-based laser with a well layer based on InGa(Al)P, e.g. red laser
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Nanotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biophysics (AREA)
- Materials Engineering (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Catalysts (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1220666.0A GB201220666D0 (en) | 2012-11-16 | 2012-11-16 | Process for preparing chemical compounds |
| GB201307314A GB201307314D0 (en) | 2013-04-23 | 2013-04-23 | Process for preparing chemical compounds |
| EP13792965.9A EP2920192B1 (en) | 2012-11-16 | 2013-11-15 | Process for preparing nucleoside prodrugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1119161T1 true CY1119161T1 (el) | 2018-02-14 |
Family
ID=49622844
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20171100539T CY1119161T1 (el) | 2012-11-16 | 2017-05-24 | Μιγμα rp/sp gemcitabine-[phenyl-(benzyloxy-l-alaninyl)]-phosphate |
| CY20191100503T CY1121663T1 (el) | 2012-11-16 | 2019-05-09 | Μιγμα rp/sp gemcitαβινε- [ρηενyl-(benzyloxy-l-alανιnyl)]-phosphate |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20191100503T CY1121663T1 (el) | 2012-11-16 | 2019-05-09 | Μιγμα rp/sp gemcitαβινε- [ρηενyl-(benzyloxy-l-alανιnyl)]-phosphate |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US10005810B2 (enExample) |
| EP (3) | EP3235824B1 (enExample) |
| JP (5) | JP2016506371A (enExample) |
| KR (1) | KR20150103669A (enExample) |
| CN (2) | CN104903339A (enExample) |
| AU (1) | AU2013346515B2 (enExample) |
| CA (1) | CA2891266C (enExample) |
| CL (1) | CL2015001307A1 (enExample) |
| CY (2) | CY1119161T1 (enExample) |
| DK (2) | DK3150616T3 (enExample) |
| EA (1) | EA028871B1 (enExample) |
| ES (3) | ES2725491T3 (enExample) |
| HR (2) | HRP20170791T1 (enExample) |
| HU (2) | HUE033335T2 (enExample) |
| IL (1) | IL238792A (enExample) |
| IN (1) | IN2015DN04090A (enExample) |
| LT (2) | LT3235824T (enExample) |
| MX (1) | MX374779B (enExample) |
| MY (1) | MY176133A (enExample) |
| NZ (1) | NZ708177A (enExample) |
| PH (1) | PH12015501090B1 (enExample) |
| PL (2) | PL3235824T3 (enExample) |
| PT (2) | PT3150616T (enExample) |
| RS (2) | RS58849B1 (enExample) |
| SG (3) | SG10201510324YA (enExample) |
| SI (2) | SI3235824T1 (enExample) |
| SM (2) | SMT201700349T1 (enExample) |
| WO (1) | WO2014076490A1 (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0317009D0 (en) | 2003-07-21 | 2003-08-27 | Univ Cardiff | Chemical compounds |
| CN104903339A (zh) | 2012-11-16 | 2015-09-09 | 卡迪夫大学学院顾问有限公司 | 用于制备核苷前体药物的方法 |
| US10034893B2 (en) | 2013-02-01 | 2018-07-31 | Enanta Pharmaceuticals, Inc. | 5, 6-D2 uridine nucleoside/tide derivatives |
| WO2015081133A2 (en) * | 2013-11-27 | 2015-06-04 | Idenix Pharmaceuticals, Inc. | Nucleotides for the treatment of liver cancer |
| CN105153257B (zh) * | 2014-06-12 | 2019-03-05 | 正大天晴药业集团股份有限公司 | 索非布韦的制备方法 |
| PL3160978T3 (pl) * | 2014-06-25 | 2020-11-30 | NuCana plc | Proleki gemcytabiny |
| EA033046B1 (ru) | 2014-06-25 | 2019-08-30 | НУКАНА ПиЭлСи | Состав, содержащий пролекарство гемцитабина |
| CN105254694B (zh) * | 2014-07-14 | 2018-11-27 | 正大天晴药业集团股份有限公司 | 氘代核苷衍生物 |
| JP6646663B2 (ja) | 2014-07-22 | 2020-02-14 | ニューカナ バイオメッド リミテッドＮｕｃａｎａ Ｂｉｏｍｅｄ Ｌｉｍｉｔｅｄ | ゲムシタビン−［フェニル（ベンゾキシ−ｌ−アラニニル）］ホスフェートの製造方法リン酸誘導体を製造する方法 |
| JP2017522343A (ja) * | 2014-07-31 | 2017-08-10 | サンド・アクチエンゲゼルシヤフト | ホスホルアミデート類の合成 |
| WO2016033164A1 (en) | 2014-08-26 | 2016-03-03 | Enanta Pharmaceuticals, Inc. | Nucleoside and nucleotide derivatives |
| CN105461774B (zh) * | 2014-09-30 | 2020-11-24 | 江苏豪森药业集团有限公司 | 索非布韦的制备方法 |
| CN105461773B (zh) * | 2014-09-30 | 2020-12-01 | 江苏豪森药业集团有限公司 | 索非布韦的制备方法及其中间体 |
| GB201417644D0 (en) * | 2014-10-06 | 2014-11-19 | Nucana Biomed Ltd | Method of separating phosphate diastereoisomers |
| WO2016073756A1 (en) | 2014-11-06 | 2016-05-12 | Enanta Pharmaceuticals, Inc. | Deuterated nucleoside/tide derivatives |
| US9732110B2 (en) | 2014-12-05 | 2017-08-15 | Enanta Pharmaceuticals, Inc. | Nucleoside and nucleotide derivatives |
| MY190867A (en) | 2015-03-06 | 2022-05-13 | Atea Pharmaceuticals Inc | ? -d-2'-deoxy-2'-?-fluoro-2'- ? -c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment |
| EP3274356A1 (en) | 2015-03-26 | 2018-01-31 | Química Sintética, S.A. | Nucleoside phosphoramidates useful for the treatment of viral infections and preparation thereof |
| CN106397515B (zh) * | 2015-07-28 | 2021-05-11 | 广东东阳光药业有限公司 | 一种改良的索菲布韦制备方法 |
| CN106543252A (zh) * | 2015-09-16 | 2017-03-29 | 博瑞生物医药（苏州）股份有限公司 | 核苷氨基磷酸酯类前药的制备方法及其中间体 |
| CN112156102B (zh) * | 2015-09-16 | 2023-10-03 | 济南高合医疗科技有限公司 | 一种nuc-1031单一异构体的晶型及其制备方法 |
| CN106543220A (zh) * | 2015-09-16 | 2017-03-29 | 博瑞生物医药（苏州）股份有限公司 | 氨基磷酸酯化合物及其制备方法和晶体 |
| WO2017060661A1 (en) | 2015-10-05 | 2017-04-13 | Nucana Biomed Limited | Combination therapy |
| WO2017090264A1 (ja) * | 2015-11-27 | 2017-06-01 | 大原薬品工業株式会社 | ５－アザシチジン又は其の２'－デオキシ体の５'位ジベンジル燐酸エステル |
| SG11201804774YA (en) * | 2015-12-11 | 2018-07-30 | NuCana plc | Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug nuc-1031 |
| GB201522771D0 (en) * | 2015-12-23 | 2016-02-03 | Nucana Biomed Ltd | Crystalline form of a phosphate derivative |
| GB201609602D0 (en) * | 2016-06-01 | 2016-07-13 | Nucuna Biomed Ltd | Chemical compounds |
| US10202412B2 (en) | 2016-07-08 | 2019-02-12 | Atea Pharmaceuticals, Inc. | β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections |
| US10711029B2 (en) | 2016-07-14 | 2020-07-14 | Atea Pharmaceuticals, Inc. | Beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-c-substituted-4′fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection |
| US10239910B2 (en) * | 2016-07-20 | 2019-03-26 | Optimus Drugs (P) Limited | Process for the preparation of sofosbuvir |
| WO2018019188A1 (zh) * | 2016-07-23 | 2018-02-01 | 博瑞生物医药（苏州）股份有限公司 | 核苷氨基磷酸酯类前药的多晶型及其制备方法 |
| PL3512863T3 (pl) | 2016-09-07 | 2022-04-04 | Atea Pharmaceuticals, Inc. | 2'-Podstawione-N6-podstawione nukleotydy purynowe do leczenia zakażeń wirusem RNA |
| US10266558B2 (en) * | 2016-10-07 | 2019-04-23 | Alexandre Vasilievich Ivachtchenko | Macroheterocyclic nucleoside derivatives and their analogues, production and use thereof |
| CN109863160B (zh) * | 2016-12-23 | 2022-06-07 | 四川科伦博泰生物医药股份有限公司 | 核苷磷酸类化合物及其制备方法和用途 |
| IL295609B2 (en) | 2017-02-01 | 2023-11-01 | Atea Pharmaceuticals Inc | Nucleotide hemisulfate salt for the treatment of hepatitis C virus |
| GB201709471D0 (en) | 2017-06-14 | 2017-07-26 | Nucana Biomed Ltd | Diastereoselective synthesis of hosphate derivatives |
| CN112351799A (zh) | 2018-04-10 | 2021-02-09 | 阿堤亚制药公司 | 具有硬化的hcv感染患者的治疗 |
| EP3808752A4 (en) | 2018-06-12 | 2022-03-09 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | PHOSPHONAMIDE ESTER COMPOUND, SALT THEREOF, ASSOCIATED CRYSTALLINE FORM THEREOF, METHOD FOR PREPARATION AND USE |
| US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
| RU2740058C1 (ru) * | 2020-06-26 | 2020-12-31 | Общество С Ограниченной Ответственностью "Технология Лекарств" | Способ получения софосбувира и фосфорамидаты |
| CN112409431B (zh) * | 2020-12-07 | 2023-04-21 | 武汉伯瑞恒医药科技有限公司 | 阿糖胞苷结构类似物及其制备方法和用途 |
| BR112023026356A2 (pt) | 2021-06-17 | 2024-03-05 | Atea Pharmaceuticals Inc | Método para tratar vírus da hepatite c ou uma condição resultante de uma infecção por hepatite c, combinação, uso da combinação, composição farmacêutica, e, kit para o tratamento de vírus da hepatite c |
| CN113549076B (zh) * | 2021-07-23 | 2022-12-06 | 中国药科大学 | 一种多取代嘌呤类化合物及其制备方法和应用 |
| WO2024107859A1 (en) * | 2022-11-15 | 2024-05-23 | Rome Therapeutics, Inc. | Cyclopentene-oxymethylene phosphonamidates and related compounds and their use in treating medical conditions |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5827727A (en) | 1990-02-01 | 1998-10-27 | Emory University | Method of resolution of 1,3-oxathiolane nucleoside enantiomers |
| US5204466A (en) * | 1990-02-01 | 1993-04-20 | Emory University | Method and compositions for the synthesis of bch-189 and related compounds |
| US6703396B1 (en) | 1990-02-01 | 2004-03-09 | Emory University | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
| IL137164A0 (en) | 1998-01-23 | 2001-07-24 | Newbiotics Inc | Enzyme catalyzed therapeutic agents |
| US7462605B2 (en) | 1998-01-23 | 2008-12-09 | Celmed Oncology (Usa), Inc. | Phosphoramidate compounds and methods of use |
| US20040002476A1 (en) | 2002-02-14 | 2004-01-01 | Stuyver Lieven J. | Modified fluorinated nucleoside analogues |
| WO2004041203A2 (en) | 2002-11-04 | 2004-05-21 | Xenoport, Inc. | Gemcitabine prodrugs, pharmaceutical compositions and uses thereof |
| GB0317009D0 (en) * | 2003-07-21 | 2003-08-27 | Univ Cardiff | Chemical compounds |
| GB0505781D0 (en) * | 2005-03-21 | 2005-04-27 | Univ Cardiff | Chemical compounds |
| CA2618335C (en) * | 2005-08-15 | 2015-03-31 | F.Hoffmann-La Roche Ag | Antiviral phosphoramidates of 4'-substituted pronucleotides |
| GB0623493D0 (en) * | 2006-11-24 | 2007-01-03 | Univ Cardiff | Chemical compounds |
| US7964580B2 (en) * | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| PA8852101A1 (es) * | 2008-12-08 | 2010-07-27 | Medivir Ab | Nucleótidos uracil ciclopropílicos |
| JP2012514657A (ja) | 2009-01-09 | 2012-06-28 | ユニバーシテイ・カレツジ・オブ・カーデイフ・コンサルタンツ・リミテツド | ウィルス感染を治療するためのグアノシンヌクレオシド化合物のホスホルアミダート誘導体 |
| TWI598358B (zh) * | 2009-05-20 | 2017-09-11 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
| TW201136945A (en) * | 2010-03-31 | 2011-11-01 | Pharmasset Inc | Purine nucleoside phosphoramidate |
| NZ606141A (en) * | 2010-07-19 | 2015-03-27 | Gilead Sciences Inc | Methods for the preparation of diasteromerically pure phosphoramidate prodrugs |
| CA2810928A1 (en) * | 2010-09-22 | 2012-03-29 | Alios Biopharma, Inc. | Substituted nucleotide analogs |
| AU2011349278C1 (en) * | 2010-12-22 | 2017-01-19 | Alios Biopharma, Inc. | Cyclic nucleotide analogs |
| SI2681227T1 (sl) * | 2011-03-01 | 2016-04-29 | Nucana Biomed Limited | Fosforamidatni derivati 5-fluoro-2'-deoksiuridina za uporabo pri zdravljenju raka |
| CN110152000A (zh) * | 2011-03-02 | 2019-08-23 | J·深塔格 | 用于单独治疗肝脂肪变性或治疗伴有丙型肝炎病毒感染的肝脂肪变性的组合物 |
| US20150272885A1 (en) * | 2011-10-14 | 2015-10-01 | Stc.Unm | Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery including transdermal delivery of cargo and methods thereof |
| CN104903339A (zh) | 2012-11-16 | 2015-09-09 | 卡迪夫大学学院顾问有限公司 | 用于制备核苷前体药物的方法 |
| US9815864B2 (en) * | 2013-06-26 | 2017-11-14 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| PL3043803T3 (pl) | 2013-09-11 | 2022-11-07 | Emory University | Kompozycje nukleotydowe i nukleozydowe oraz ich zastosowanie |
| EP3055319A4 (en) * | 2013-10-11 | 2018-01-10 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| AU2014354957A1 (en) * | 2013-11-27 | 2016-06-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Piperidine and piperazine derivatives and their use in treating viral infections and cancer |
| WO2015081133A2 (en) | 2013-11-27 | 2015-06-04 | Idenix Pharmaceuticals, Inc. | Nucleotides for the treatment of liver cancer |
| EA033046B1 (ru) | 2014-06-25 | 2019-08-30 | НУКАНА ПиЭлСи | Состав, содержащий пролекарство гемцитабина |
| PL3160978T3 (pl) | 2014-06-25 | 2020-11-30 | NuCana plc | Proleki gemcytabiny |
| JP6646663B2 (ja) | 2014-07-22 | 2020-02-14 | ニューカナ バイオメッド リミテッドＮｕｃａｎａ Ｂｉｏｍｅｄ Ｌｉｍｉｔｅｄ | ゲムシタビン−［フェニル（ベンゾキシ−ｌ−アラニニル）］ホスフェートの製造方法リン酸誘導体を製造する方法 |
| GB201417644D0 (en) | 2014-10-06 | 2014-11-19 | Nucana Biomed Ltd | Method of separating phosphate diastereoisomers |
| KR20180021697A (ko) | 2015-05-14 | 2018-03-05 | 뉴카나 피엘씨 | 암 치료 |
| WO2017060661A1 (en) | 2015-10-05 | 2017-04-13 | Nucana Biomed Limited | Combination therapy |
| SG11201804774YA (en) | 2015-12-11 | 2018-07-30 | NuCana plc | Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug nuc-1031 |
| CA3008749C (en) | 2015-12-23 | 2024-01-02 | NuCana plc | Treatment of ovarian cancer or biliary tract cancer with a combination of gemcitabine-(phenyl-benzoxy-l-alaninyl)]-phosphate and cisplatin |
| CA3008769A1 (en) | 2015-12-23 | 2017-06-29 | NuCana plc | Combination therapy comprising nuc-1031 and cisplatin |
| GB201522771D0 (en) | 2015-12-23 | 2016-02-03 | Nucana Biomed Ltd | Crystalline form of a phosphate derivative |
| GB201713914D0 (en) | 2017-08-30 | 2017-10-11 | Nucana Biomed Ltd | Combination therapy |
| JP2020171815A (ja) * | 2020-07-29 | 2020-10-22 | 株式会社ユニバーサルエンターテインメント | プログラム |
-
2013
- 2013-11-15 CN CN201380069952.2A patent/CN104903339A/zh active Pending
- 2013-11-15 SM SM20170349T patent/SMT201700349T1/it unknown
- 2013-11-15 DK DK16195036.5T patent/DK3150616T3/en active
- 2013-11-15 EA EA201590955A patent/EA028871B1/ru unknown
- 2013-11-15 SI SI201331437T patent/SI3235824T1/sl unknown
- 2013-11-15 SG SG10201510324YA patent/SG10201510324YA/en unknown
- 2013-11-15 PT PT161950365T patent/PT3150616T/pt unknown
- 2013-11-15 SM SM20190341T patent/SMT201900341T1/it unknown
- 2013-11-15 PT PT17169878T patent/PT3235824T/pt unknown
- 2013-11-15 ES ES17169878T patent/ES2725491T3/es active Active
- 2013-11-15 US US14/442,987 patent/US10005810B2/en active Active
- 2013-11-15 PL PL17169878T patent/PL3235824T3/pl unknown
- 2013-11-15 NZ NZ708177A patent/NZ708177A/en not_active IP Right Cessation
- 2013-11-15 ES ES16195036.5T patent/ES2627195T3/es active Active
- 2013-11-15 WO PCT/GB2013/053018 patent/WO2014076490A1/en not_active Ceased
- 2013-11-15 EP EP17169878.0A patent/EP3235824B1/en active Active
- 2013-11-15 SG SG10201510322UA patent/SG10201510322UA/en unknown
- 2013-11-15 AU AU2013346515A patent/AU2013346515B2/en not_active Ceased
- 2013-11-15 RS RS20190549A patent/RS58849B1/sr unknown
- 2013-11-15 IN IN4090DEN2015 patent/IN2015DN04090A/en unknown
- 2013-11-15 HU HUE16195036A patent/HUE033335T2/en unknown
- 2013-11-15 ES ES13792965.9T patent/ES2618732T3/es active Active
- 2013-11-15 SG SG11201503750YA patent/SG11201503750YA/en unknown
- 2013-11-15 EP EP16195036.5A patent/EP3150616B1/en active Active
- 2013-11-15 HU HUE17169878 patent/HUE044605T2/hu unknown
- 2013-11-15 LT LTEP17169878.0T patent/LT3235824T/lt unknown
- 2013-11-15 KR KR1020157015861A patent/KR20150103669A/ko not_active Ceased
- 2013-11-15 SI SI201330652T patent/SI3150616T1/sl unknown
- 2013-11-15 MX MX2015006195A patent/MX374779B/es active IP Right Grant
- 2013-11-15 PL PL16195036T patent/PL3150616T3/pl unknown
- 2013-11-15 CA CA2891266A patent/CA2891266C/en active Active
- 2013-11-15 JP JP2015542357A patent/JP2016506371A/ja active Pending
- 2013-11-15 EP EP13792965.9A patent/EP2920192B1/en not_active Not-in-force
- 2013-11-15 MY MYPI2015001314A patent/MY176133A/en unknown
- 2013-11-15 RS RS20170506A patent/RS56038B1/sr unknown
- 2013-11-15 DK DK17169878.0T patent/DK3235824T3/da active
- 2013-11-15 CN CN202010526209.7A patent/CN111592577A/zh active Pending
- 2013-11-15 LT LTEP16195036.5T patent/LT3150616T/lt unknown
-
2015
- 2015-05-13 IL IL238792A patent/IL238792A/en active IP Right Grant
- 2015-05-14 CL CL2015001307A patent/CL2015001307A1/es unknown
- 2015-05-15 PH PH12015501090A patent/PH12015501090B1/en unknown
-
2017
- 2017-05-24 CY CY20171100539T patent/CY1119161T1/el unknown
- 2017-05-29 HR HRP20170791TT patent/HRP20170791T1/hr unknown
- 2017-08-10 JP JP2017154931A patent/JP2018009000A/ja not_active Withdrawn
-
2018
- 2018-05-31 US US15/994,378 patent/US11040997B2/en active Active
-
2019
- 2019-05-06 HR HRP20190831TT patent/HRP20190831T1/hr unknown
- 2019-05-09 CY CY20191100503T patent/CY1121663T1/el unknown
- 2019-06-18 JP JP2019112739A patent/JP2019196360A/ja active Pending
-
2020
- 2020-10-12 JP JP2020171815A patent/JP7519259B2/ja active Active
-
2021
- 2021-05-18 US US17/323,367 patent/US20220033433A1/en not_active Abandoned
-
2023
- 2023-01-20 JP JP2023007007A patent/JP2023052536A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1119161T1 (el) | Μιγμα rp/sp gemcitabine-[phenyl-(benzyloxy-l-alaninyl)]-phosphate | |
| EP2935303A4 (en) | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGUE THEREOF | |
| CL2011000718A1 (es) | Proceso para la preparacion de compuestos fosforados enantiomericos. | |
| CY1123061T1 (el) | Μεθοδοι διαχωρισμου διαστερεοϊσομερων φωσφορικης γεμσιταβινης | |
| CY1118472T1 (el) | Υποκατεστημενα ακυλανιλιδια και μεθοδοι χρησης αυτων | |
| BR112013029761A2 (pt) | pró-drogas de monofosfato de purina para tratamento de infecções virais | |
| MX378692B (es) | Clase novedosa de genes de resistencia a glifosato. | |
| CO7240361A2 (es) | Composiciones de arni de serpinc1 y métodos de uso de las mismas | |
| EP2971353A4 (en) | COMBINED RAILWAYS AND METHOD FOR THE PRODUCTION AND USE THEREOF | |
| CO6990719A2 (es) | Derivados de los nucleósidos sustituidos en 4´-azido, 3´-fluoro como inhibidores de la replicación del rna del vhc | |
| EA201491040A1 (ru) | Замещенные нуклеозиды, нуклеотиды и их аналоги | |
| BR112015006874A2 (pt) | ligantes de rig-i inovadores e métodos para produzir os mesmos | |
| CL2013000076A1 (es) | Metodos para la preparacion de profarmacos de fosforamidato diastereomericamente puros. | |
| CO6821972A2 (es) | Proceso para la producción de carbonato de calcio precipitado, carbonato de calcio precipitado y sus usos | |
| EP2841616A4 (en) | COATINGS, COATED SURFACES AND METHOD FOR THE PRODUCTION THEREOF | |
| NZ630596A (en) | Methods for treatment of alport syndrome | |
| CY1124809T1 (el) | Διαστεροεπιλεκτικη συνθεση φωσφορικων παραγωγων και προφαρμακου γεμσιταβινης nuc-1031 | |
| BR112016010573A8 (pt) | composições de fertilizantes | |
| ZA201503644B (en) | Antiviral phosphonate analogues and process for preparation thereof | |
| CY1122447T1 (el) | Μεθοδος παρασκευης προϊοντων με βαση τα ολοκληρα τεμαχια κρεατος και μορφοποιημενων προϊοντων με βαση το κρεας, που περιεχουν ελαιο | |
| EA201692288A1 (ru) | Способ получения фосфорсодержащих циангидринов | |
| BR112015006510A2 (pt) | catalisador de reforma de vapor e método de produção do mesmo | |
| MX2018002730A (es) | Proceso para producir esteres de cianhidrina que contienen fosforo. | |
| EP2998023A4 (en) | SOLID PHOSPHORIC ACID CATALYST AND METHOD FOR PREPARING TRIOXAN | |
| PH12020550728A1 (en) | Salts of diphosphate phosphoramidate of nucleosides as anticancer compounds |